Cellarity, Flagship's $50M bet on Network Biology, Marries Machine Learning and Single-Cell Tech for Drug Discovery

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease